Noble Financial Issues Positive Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Noble Financial boosted their Q3 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research report issued on Tuesday, March 31st. Noble Financial analyst R. Leboyer now expects that the company will post earnings of $0.79 per share for the quarter, up from their previous forecast of $0.74. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

A number of other brokerages also recently weighed in on UNCY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Westpark Capital started coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Guggenheim reissued a “buy” rating on shares of Unicycive Therapeutics in a report on Tuesday, December 30th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

Unicycive Therapeutics Trading Up 8.2%

Shares of NASDAQ UNCY opened at $7.12 on Wednesday. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00. The firm has a market capitalization of $179.71 million, a price-to-earnings ratio of -3.28 and a beta of 1.81. The business has a 50-day moving average of $6.67 and a 200-day moving average of $5.78.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after buying an additional 10,400 shares during the last quarter. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the second quarter valued at approximately $55,000. JPMorgan Chase & Co. raised its stake in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Unicycive Therapeutics during the fourth quarter worth approximately $226,000. Finally, Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth approximately $182,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.